Tractinostat Drug Asset Due Diligence Report 2026

This Tractinostat Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Tractinostat can convert its Small molecule drug profile and HDACs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Tractinostat (query alias: Tractinostat)
Modality / target	Small molecule drug; HDACs; HDAC inhibitors, Epigenetic drug
Highest global status	Phase 2
Originator	Chroma Therapeutics Ltd.
Active developers	Chroma Therapeutics Ltd.

The MCP disease footprint includes Multiple Myeloma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06302140	Phase 1	Terminated	8	Primary endpoint not disclosed in English source
NL-OMON51840	Not Applicable	Withdrawn	6	Primary endpoint not disclosed in English source
NCT05166577	Phase 1	Terminated	26	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Open-Label Multicenter Phase 1b/2 Study of Nanatinostat + Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1; n=26; evaluation: Not stated in English source. Reported fields: Phase 1b: Incidence of Dose-Limiting Toxicities (DLTs) = 0 Pts ; Phase 1b: Incidence of Dose-Limiting Toxicities (DLTs) = 0 Pts

TCL-737 A Global Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With EBV-Positive (EBV+) Relapsed/Refractory Peripheral T Cell Lymphomas (NAVAL-1)

Not Applicable; n=not disclosed; evaluation: Not stated in English source. Reported fields: Adverse Event: Grade 3-4 TRAEs = most Grade 3-4 TRAEs have been haematologic in nature and generally manageable or reversible with only one Grade 5 TRAE ; Adverse Event: Grade 3-4 TRAEs = most Grade 3-4 TRAEs have been haematologic in nature and generally manageable or reversible with only one Grade 5 TRAE

Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study

Phase 1/2; n=55; evaluation: Not stated in English source. Reported fields: Adverse Event: Grade 3/4 neutropenia = 29%

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Tractinostat addresses Multiple Myeloma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2021-08-23	Viracta Therapeutics Reacquires Exclusive Development and Commercialization Rights for its All-Oral Combination Therapy in China	Phase 2	US$4.0M stated total
2016-11-30	Viracta acquires Phase 2 epigenetic drug candidate from Chroma Therapeutics	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Lasofoxifene treatment of er+ cancers with constitutively active ESR1 mutations”. The milestone feed surfaced a patent-application signal described as “MEF2 transcriptional activators to treat neurologic conditions”. The milestone feed surfaced a patent-application signal described as “Hydrogel pharmaceutical compositions”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO